Fundraising FoxPolaris Partners — 2017 Investments
9 investments dated 2017 · listed companies and verified rows first · show all
Cardlytics operates a commerce media platform that uses card-linked purchase data to deliver targeted offers and closed-loop measurement for marketers and advertisers, and personalized rewards programs for banks and publishers.
AdTechFintechMarketing TechAtlanta, US
Scott Grimes(Founder)inLynne Laube(Founder)inKirk Somers(Executive Officer)inDavid Evans(Executive Officer)inAmit Gupta(Chief Executive Officer and Director)in
BoardJohn Klinck(Director)in
Board seatBryce Youngren· per SEC Form D · $11.9M raise · filed Jun 2017
Co-investorsBaroda VenturesCanaan PartnersKinetic Ventures, L.L.C.Next Coast VenturesSavano Capital PartnersDiscovery Capital+2 more
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)Yung H. Chyung(Executive Officer)Elan Z. Ezickson(Executive Officer)Akshay Vaishnaw(President of Research & Development and Director)R. Keith Woods(Chief Operating Officer)in
Board seatAmir Nashat· per SEC Form D · $47M raise · filed Jan 2018
Co-investorsSamsara BioCapitalARCH Venture PartnersEcoR1 Capital
Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples.
BiotechDeep TechHardwareHealthtechBoston, US
Omid Farokhzad(Founder)inPhilip Ma(Executive Officer)Shadi Aryanpour(Executive Officer)David Singer(Director)Omid Cameron Farokhzad(Founder)in
Board seatTerrance McGuire· per SEC Form D · $6M raise · filed Jan 2018
Co-investorsSoftBank Vision FundSolasta VenturesWingaMoonMaverick VenturesT. Rowe Price
Vaccinex is a clinical-stage biotechnology company developing pepinemab (VX15/2503), a humanized monoclonal antibody that blocks SEMA4D signaling, in trials for neurological disorders such as Huntington's and Alzheimer's disease and for solid tumors including breast cancer, melanoma, non-small cell lung cancer and head and neck cancer.
BiotechHealthtechMedical DevicesRochester, US
Maurice Zauderer, Ph.D.(President and CEO)Maurice Zauderer(Executive Officer, Director)inErnest S. Smith Ph.D.(Executive Officer)Jill Sanchez(Executive Officer)inErnest S. Smith(Executive Officer)inRaymond Watkins(Executive Officer)in
Board seatAlan Crane· per SEC Form D · $18.2M raise · filed Jul 2017
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon, US
Riley Ennis(Founder)inCharles Roberts(Founder)inGabriel Otte(Founder)inAdam Stone(Chief Executive Officer and Director)Michael Altman(Chief Business Officer and Director)Shmuel (Sam) M. Cohn(Chief Financial Officer)
Co-investorsRA CapitalAgent CapitalAME Cloud VenturesAndreessen HorowitzArtis VenturesAsset Management Company+15 more
Seattle 'scientific wellness' startup that paired genetic, blood and microbiome testing with health coaching; closed in 2019.
HealthtechSeattle, US
Nathan Price(Director)Clayton Lewis(Executive Officer, Director)
BoardTim Kilgallon(Director)
Board seatTerry McGuire· per SEC Form D · $30M raise · filed Jun 2017
Co-investorsCorewell Health VenturesARCH Venture Partners
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.
AI & Machine LearningBiotechDeep TechAustin, US
Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)
Board seatTerrance G. McGuire· per SEC Form D
Co-investorsAvalon BioVenturesBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalPfizer VenturesVersant Ventures
Swiftly provides a data platform for public transit agencies to track vehicle locations, generate real-time passenger information and arrival predictions, and analyze historical operations data.
Data & InfrastructureGovTechMobility & Transportation
Co-investorsBuilders + BackersJMI EquityPlug and Play VenturesRenewal FundsSHAKTIVia ID+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.